Cargando…

Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis

PURPOSE: The aim of this study was to investigate the comparative risks of budesonide/formoterol, versus placebo or monotherapies, for the treatment of patients with stable COPD. MATERIALS AND METHODS: We undertook a systematic search of the literature in PubMed, Embase, and the Cochrane Central Reg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Bin, Wang, Jun, Luo, Lin-lin, Li, Qiu-gen, Huang, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448539/ https://www.ncbi.nlm.nih.gov/pubmed/31015757 http://dx.doi.org/10.2147/COPD.S192166

Ejemplares similares

Comparative Efficacy of Budesonide/Formoterol with Budesonide, Formoterol or Placebo for Stable Chronic Obstructive Pulmonary Disease: A Meta-Analysis
por: Tang, Bin, et al.
Publicado: (2019)

Budesonide–formoterol (inhalation powder) in the treatment of COPD
por: Ceylan, Erkan
Publicado: (2006)

Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Guo, Min, et al.
Publicado: (2022)

Budesonide/formoterol combination in COPD: a US perspective
por: Sharafkhaneh, Amir, et al.
Publicado: (2010)

Correction to: Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Retracted: The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
por: Calverley, Peter M, et al.
Publicado: (2016)

Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma
por: Morice, A H, et al.
Publicado: (2007)

Metabolic changes of different high-resolution computed tomography phenotypes of COPD after budesonide–formoterol treatment
por: Wang, Cheng, et al.
Publicado: (2017)

Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study
por: Ferguson, Gary T., et al.
Publicado: (2018)

A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler(®) to Budesonide/Formoterol Easyhaler(®)
por: Syk, Jörgen, et al.
Publicado: (2019)

Budesonide/Formoterol Enhances the Expression of Pro Surfactant Protein-B in Lungs of COPD Patients
por: Um, Soo Jung, et al.
Publicado: (2013)

Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
por: Hanania, Nicola A., et al.
Publicado: (2020)

Correction to: A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler(®) to Budesonide/Formoterol Easyhaler(®)
por: Syk, Jörgen, et al.
Publicado: (2019)

Long-term safety of budesonide/formoterol for the treatment of elderly patients with bronchial asthma
por: KAGOHASHI, KATSUNORI, et al.
Publicado: (2014)

Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments
por: Trudo, Frank, et al.
Publicado: (2015)

Comparison of Aerosol Formulations of Formoterol Fumarate and Budesonide
por: Nirale, N. M., et al.
Publicado: (2011)

Protocol: Influence of Budesonide and Budesonide/Formoterol on Asthma Control in Smoking Asthmatic Adults
por: Boulet, Louis-Philippe, et al.
Publicado: (2010)

Tolerability of budesonide/formoterol in patients of Kazakhstan rural regions
por: Nurpeissov, Tair, et al.
Publicado: (2015)

Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group, multicentre study
por: Ställberg, Björn, et al.
Publicado: (2009)

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids
por: van den Berge, Maarten, et al.
Publicado: (2021)

Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study
por: Portillo, Edward C., et al.
Publicado: (2023)

Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2012)

Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis
por: Bourdin, Arnaud, et al.
Publicado: (2021)

Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol
por: Bateman, ED, et al.
Publicado: (2006)

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations
por: Kuna, P, et al.
Publicado: (2007)

Effect of adjusting the combination of budesonide/formoterol on the alleviation of asthma symptoms
por: Souma, Ryosuke, et al.
Publicado: (2018)

A randomized, double-blinded, double-dummy efficacy and safety study of budesonide–formoterol Spiromax® compared to budesonide–formoterol Turbuhaler® in adults and adolescents with persistent asthma
por: Virchow, J. Christian, et al.
Publicado: (2016)

Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS
por: Wang, Chen, et al.
Publicado: (2020)

Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life
por: Price, David B, et al.
Publicado: (2007)

Effects of treatment with montelukast alone, budesonide/formoterol alone and a combination of both in cough variant asthma
por: Yi, Fang, et al.
Publicado: (2022)

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting
por: Perrone, Valentina, et al.
Publicado: (2016)

Efficacy of budesonide/formoterol and tiotropium combination for the treatment of Chinese patients with chronic obstructive pulmonary disease
por: Feng, Jun-fei, et al.
Publicado: (2018)

Budesonide and formoterol effects on rhinovirus replication and epithelial cell cytokine responses
por: Bochkov, Yury A, et al.
Publicado: (2013)

The rapid effects of budesonide plus formoterol in patients with obstructive airway diseases
por: Bayiz, Hulya, et al.
Publicado: (2015)

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting [Corrigendum]
Publicado: (2017)

Is It Really Feasible to Use Budesonide–Formoterol as Needed for Mild Persistent Asthma? A Systematic Review and Meta-Analysis
por: Tong, Xiang, et al.
Publicado: (2021)

Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study
por: Kerwin, Edward M., et al.
Publicado: (2019)

Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study
por: Price, David B., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ro17m9cclbj9d7iolj120qp3jm